AG 494
CAS: 133550-35-3
Ref. 3D-IFA55035
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued |
Product Information
- (2E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-phenyl-2-propenamide
- (2E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-phenylacrylamide
- (2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-phenylprop-2-enamide
- 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-N-phenyl-, (2E)-
- 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-N-phenyl-, (E)-
- Ag 494
- Tyrphostin AG 494
AG 494 is a pharmaceutical preparation that is used to treat diabetic neuropathy. AG 494 is a growth factor that activates the caco-2 cells. It also has been shown to have an anti-inflammatory effect on inflammatory diseases, such as Crohn's disease and ulcerative colitis. AG 494 is also a pharmacological agent for the treatment of inflammatory bowel disease and cancer. AG 494 inhibits lipid kinase activity, thereby inhibiting the production of lipids in cancer cells, which may lead to cell death by apoptosis or necrosis. In addition, AG 494 is a monoclonal antibody that targets the toll-like receptor 4 (TLR-4) pathway in cancer cells and suppresses their growth.